Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.39 |
| ▸ | JAK3 | P52333 | 8/20 | 0.38 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | STK10 | O94804 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FER | P16591 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | STAT5A | P42229 | 1/20 | 0.34 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694119 | 1.00 | JAK2 (0.39) | JAK2JAK3AGBL2NPC1NTRK1 | |
| SCHEMBL3024437 | 0.93 | L3MBTL1 (0.37) | JAK2JAK3AGBL2 | |
| SCHEMBL14841256 | 0.85 | L3MBTL1 (0.40) | JAK2JAK3 | |
| SCHEMBL219174 | 0.85 | L3MBTL1 (0.40) | JAK2JAK3 | |
| SCHEMBL219175 | 0.85 | L3MBTL1 (0.40) | JAK2JAK3 | |
| SCHEMBL20303574 | 0.81 | ALDH1A1 (0.36) | NPC1APLNRMAPK1KDM4EALDH1A1 | |
| SCHEMBL420311 | 0.77 | NR1I2 (0.48) | JAK2JAK3NPC1NTRK1APLNR | |
| SCHEMBL1927308 | 0.77 | NR1I2 (0.48) | JAK2JAK3NPC1NTRK1APLNR | |
| SCHEMBL1693620 | 0.77 | NR1I2 (0.48) | JAK2JAK3NPC1NTRK1APLNR | |
| SCHEMBL12354684 | 0.77 | KMT2A (0.44) | ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011545-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20140155394-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2014-06-05 | — | — | US | disclosed |
| EP-2152702-B1 | AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2011-08-24 | — | — | EP | disclosed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20100204231-A1 | AMINO-THIAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-08-12 | — | — | US | disclosed |
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-08-12 | — | — | US | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ABL1, MCL1, ETV6 | JAK2 4/4885JAK3 10/4885AGBL2 3432/4885 |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885AGBL2 3705/4885 |
| US-20100204231-A1 | AMINO-THIAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, TYMP, TPMT | JAK2 8/4885JAK3 31/4885AGBL2 3561/4885 |
| US-20150011545-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | JAK2 15/4885JAK3 363/4885AGBL2 3920/4885 |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | JAK2 6/4885JAK3 188/4885AGBL2 3000/4885 |
| US-20140155394-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | JAK2 15/4885JAK3 363/4885AGBL2 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.